Tenofovir Disoproxil Fumarate: a Review of Its Use in the Management of HIV Infection

Overview

Journal Drugs

Specialty Pharmacology

Date 2005 Jan 27

PMID 15669881

Citations 27

Authors

Katherine A Lyseng-Williamson

Neil A Reynolds

Greg L Plosker

Affiliations

Soon will be listed here.

Abstract

Tenofovir disoproxil fumarate (tenofovir DF; Viread), an ester prodrug of the nucleotide reverse transcriptase inhibitor (NRTI) tenofovir, is indicated in combination with other antiretroviral agents in the treatment of HIV infection. As a component of an antiretroviral regimen, oral tenofovir DF 300 mg once daily effectively reduces viral load in patients with HIV infection who are treatment-experienced with baseline NRTI resistance mutations or treatment-naive. Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication.

Citing Articles

Nucleoside Reverse Transcriptase Inhibitors Are the Major Class of HIV Antiretroviral Therapeutics That Induce Neuropathic Pain in Mice.

Bush K, Wairkar Y, Tang S Int J Mol Sci. 2024; 25(16).

PMID: 39201745 PMC: 11354254. DOI: 10.3390/ijms25169059.

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts.

Dsouza L, Pant A, Offei S, Priyamvada L, Pope B, Satheshkumar P bioRxiv. 2023; .

PMID: 36993701 PMC: 10055413. DOI: 10.1101/2023.03.23.533943.

ATP/ADP biosensor organoids for drug nephrotoxicity assessment.

Susa K, Kobayashi K, Galichon P, Matsumoto T, Tamura A, Hiratsuka K Front Cell Dev Biol. 2023; 11:1138504.

PMID: 36936695 PMC: 10017499. DOI: 10.3389/fcell.2023.1138504.

A Landscape of CRISPR/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects.

Tripathi S, Khatri P, Fatima Z, Pandey R, Hameed S Pathogens. 2023; 12(1).

PMID: 36678404 PMC: 9863163. DOI: 10.3390/pathogens12010056.

The Potential of to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART).

Sibiya T, Ghazi T, Chuturgoon A Nutrients. 2022; 14(15).

PMID: 35893930 PMC: 9332774. DOI: 10.3390/nu14153076.

References

Wainberg M, Turner D . Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr. 2004; 37 Suppl 1:S36-43. DOI: 10.1097/01.qai.0000137005.63376.6e. View

Miller M, Margot N, Hertogs K, Larder B, Miller V . Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids. 2001; 20(4-7):1025-8. DOI: 10.1081/NCN-100002483. View

Coca S, Perazella M . Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002; 324(6):342-4. DOI: 10.1097/00000441-200212000-00011. View

Wainberg M, Miller M, Quan Y, Salomon H, Mulato A, Lamy P . In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 2000; 4(2):87-94. DOI: 10.1177/135965359900400205. View

Miller M, Margot N, Lu B, Zhong L, Chen S, Cheng A . Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004; 189(5):837-46. DOI: 10.1086/381784. View

Hazra R, Balis F, Tullio A, DeCarlo E, Worrell C, Steinberg S . Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2003; 48(1):124-9. PMC: 310184. DOI: 10.1128/AAC.48.1.124-129.2004. View

van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, van den Mooter G . Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metab Dispos. 2000; 28(12):1394-6. View

Negredo E, Molto J, Munoz-Moreno J, Pedrol E, Ribera E, Viciana P . Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Antivir Ther. 2004; 9(3):335-42. View

Robbins B, Srinivas R, Kim C, Bischofberger N, Fridland A . Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998; 42(3):612-7. PMC: 105507. DOI: 10.1128/AAC.42.3.612. View

10.

Schooley R, Ruane P, Myers R, Beall G, Lampiris H, Berger D . Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16(9):1257-63. DOI: 10.1097/00002030-200206140-00008. View

11.

Zidek Z, Frankova D, Holy A . Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production. Antimicrob Agents Chemother. 2001; 45(12):3381-6. PMC: 90841. DOI: 10.1128/AAC.45.12.3381-3386.2001. View

12.

Benhamou Y . Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis. 2004; 38 Suppl 2:S98-103. DOI: 10.1086/381451. View

13.

Kearney B, Flaherty J, Shah J . Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004; 43(9):595-612. DOI: 10.2165/00003088-200443090-00003. View

14.

Zidek Z, Holy A, Frankova D . Antiretroviral agent (R)-9-(2-phosphonomethoxypropyl)adenine stimulates cytokine and nitric oxide production. Eur J Pharmacol. 1997; 331(2-3):245-52. DOI: 10.1016/s0014-2999(97)01004-2. View

15.

Zidek Z, Holy A, Frankova D . Immunomodulatory properties of antiviral acyclic nucleotide analogues: cytokine stimulatory and nitric oxide costimulatory effects. Int J Immunopharmacol. 1998; 19(9-10):587-97. DOI: 10.1016/s0192-0561(97)00047-7. View

16.

Margot N, Isaacson E, McGowan I, Cheng A, Schooley R, Miller M . Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002; 16(9):1227-35. DOI: 10.1097/00002030-200206140-00004. View

17.

Domingo P, Labarga P, Palacios R, Guerro M, Terron J, Elias M . Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS. 2004; 18(10):1475-8. DOI: 10.1097/01.aids.0000131343.53419.04. View

18.

Suo Z, Johnson K . Selective inhibition of HIV-1 reverse transcriptase by an antiviral inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine. J Biol Chem. 1998; 273(42):27250-8. DOI: 10.1074/jbc.273.42.27250. View

19.

Dore G, Cooper D, Pozniak A, DeJesus E, Zhong L, Miller M . Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004; 189(7):1185-92. DOI: 10.1086/380398. View

20.

Yeni P, Hammer S, Hirsch M, Saag M, Schechter M, Carpenter C . Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004; 292(2):251-65. DOI: 10.1001/jama.292.2.251. View